FDA Issues Warning on Rare Muscle Injury

by Rajashri on  August 12, 2008 at 5:10 PM Drug News
RSS Email Print This Page Comment
 FDA Issues Warning on Rare Muscle Injury
The U.S. Food and Drug Administration has warned that patients using a combination of simvastatin and anti-arrhythmia medicine amiodarone could suffer a rare fatal muscle injury.

The injury called rhabdomyolysis may lead to kidney failure or even death.
Advertisement

The FDA said it had already warned about this condition in 2002, but that patients were still being prescribed this combination.

Advertisement
Source: Medindia
RAS/L
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive